ArticleJournal of diabetes and metabolic disorders2021

Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.

Aki Okamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.